[Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Mychaluk
Johanna
J
Centre de gynécologie obstétrique, CHU d'Amiens, Amiens Cedex 1, France.
Piprot
Christine
C
Sevestre
Henri
H
Merviel
Philippe
P
Gondry
Jean
J
Fauvet
Raffaèle
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000556:secondary*; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000556:secondary*; D007416:Intestinal Perforation / Q000139:chemically induced*; D007580:Jejunal Neoplasms / Q000556:secondary*; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel